The Lymphocyte-to-Monocyte Ratio (LMR) as a Novel Biomarker for Cervical Cancer Risk Stratification in Conization Patients
<b>Background:</b> Cervical cancer remains a major global health burden, particularly in regions with limited early detection. The Loop Electrosurgical Excision Procedure (LEEP) is commonly used to diagnose and treat cervical intraepithelial neoplasia (CIN). The lymphocyte-to-monocyte ratio (LMR) is a potential biomarker for cancer risk stratification. It reflects immune function and tumor-related inflammation. Lower LMR values suggest reduced antitumor immunity and increased tumor-promoting inflammation, which are linked to cancer development and progression. This study examines relationships between preoperative LMR and histopathological outcomes after LEEP. <b>Methods:</b> This retrospective study included 374 patients undergoing the LEEP for cervical dysplasia. Preoperative LMR values were compared across four histopathological categories: negative, low-grade, high-grade lesions, and invasive carcinoma. The Kruskal-Wallis test assessed group differences, with Mann-Whitney U tests for pairwise comparisons. ROC curve analysis (<i>n</i> = 369) evaluated LMR's diagnostic performance, and logistic regression evaluated its independent predictive value. <b>Results:</b> LMR significantly differed across cytological (<i>p</i> = 0.04) and histological groups (<i>p</i> = 0.036). Post hoc analysis revealed significantly lower LMR in invasive carcinoma versus low-grade lesions in cytology and for both low- and high-grade lesions in histology. ROC analysis yielded an AUC of 0.680. An LMR cutoff <4.49 showed 82.6% sensitivity and 50.0% specificity. Stricter cutoff (<3.89) increased specificity (66.8%) but decreased sensitivity (60.9%). Both had high negative predictive values (97.7% and 96.2%) but low positive predictive values (9.9% and 10.9%). <b>Conclusions:</b> LMR may serve as a complementary biomarker to predict higher-grade cervical lesions and help rule out invasive disease, aiding patient triage in resource-limited settings.
Authors
- Márton Keszthelyi (ORCID: https://orcid.org/0000-0003-4886-3481)
- Attila Keszthelyi (ORCID: https://orcid.org/0000-0003-2263-2175)
- Nándor Ács (ORCID: https://orcid.org/0000-0002-1919-1869)
- Petra Merkely
- V. Szabó
- Lotti Lőczi (ORCID: https://orcid.org/0000-0003-3077-7796)
- Balázs Lintner
- Szabolcs Várbı́ró (ORCID: https://orcid.org/0000-0002-7109-6906)
- Richárd Tóth
- Zsófia Tóth
- Balázs Vida
- Barbara Sebők (ORCID: https://orcid.org/0000-0003-2358-307X)
- Noémi Kalas
Institutions
- Semmelweis University (HU)
- University of Szeged (HU)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2025-08-27
- DOI
- https://doi.org/10.3390/jcm14176057
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17